The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Review Article
Drug Therapy
PreviousPrevious
Volume 342:710-721 March 9, 2000 Number 10
NextNext

Vancomycin-Resistant Enterococcal Infections
Barbara E. Murray, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
Enterococci are best known as antibiotic-resistant opportunistic pathogens that are commonly recovered from patients who have received multiple courses of antibiotics and have been hospitalized for prolonged periods.1,2,3,4,5,6 These organisms were well established as a cause of endocarditis and urinary tract infections by the early 1900s,3 and members of the species Enterococcus faecalis were known to be a common cause of nosocomial infections by the early 1980s.3,7,8,9 The emergence of enterococci with resistance to vancomycin, seen predominantly in the species E. faecium, has been followed by an increase in the frequency with which this species is recovered.10 Of all enterococcal . . . [Full Text of this Article]

Historical Aspects of Enterococci and Their Resistance to Antibiotics

Intrinsic Resistance of Enterococci

Acquired Resistance to ß-Lactams and Aminoglycosides

            Aminoglycoside Resistance

            ß-Lactam Resistance

Vancomycin Resistance in Enterococci

Genes and Mechanism of Vancomycin Resistance

Mobility of Elements Containing Genes for Vancomycin Resistance

Epidemiologic Aspects

Colonization and Infection

ß-Lactam Antibiotics, with or without Aminoglycosides

Glycopeptide, Glycopeptide plus ß-Lactam, and Double ß-Lactam Combinations, with or without an Aminoglycoside

Gyrase Inhibitors

Other Drugs

Newer Drugs

Colonization

Control Efforts


Source Information

From the Division of Infectious Diseases, Departments of Medicine and Microbiology and Molecular Genetics, and the Center for the Study of Emerging and Re-Emerging Pathogens, University of Texas Medical School, Houston.

Address reprint requests to Dr. Murray at the University of Texas Medical School–Houston, 6431 Fannin, JFB 1.728, Houston, TX 77030, or at infdis@heart.med.uth.tmc.edu.

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.